Interventional, Open-label, Exploratory Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AE04621 and the Active Metabolite Lu AA40326 After Ascending Oral Doses of Lu AE04621 to Patients With Parkinson's Disease

Trial Profile

Interventional, Open-label, Exploratory Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AE04621 and the Active Metabolite Lu AA40326 After Ascending Oral Doses of Lu AE04621 to Patients With Parkinson's Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Lu AE04621 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 16 Dec 2016 Status changed from recruiting to completed.
    • 20 Jan 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 11 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top